Hematology and Oncology Archives - Page 4 of 12 - REBEL EM

REBEL Core Cast – Basics of EM – Introduction

by Ellsworth Wright posted June 1, 2022 No Comments

REBEL Core Cast – Basics of Emergency Medicine Podcast Welcome to the EMRA Basics of Emergency Medicine Podcast. I am your host EJ Wright, and the following series is an all encompassing approach to the most common chief complaints in ...

Abdominal and GastrointestinalAllergy and ImmunologyCardiovascularDermatologyEndocrine, Metabolic, Fluid, and ElectrolytesEnvironmentalHead, Eye, Ear, Nose, and ThroatHematology and OncologyInfectious DiseaseNeurologyObstetrics and GynecologyOrthopedicsRenal and GenitourinaryResuscitationThoracic and RespiratoryToxicologyTrauma

REBEL Cast Ep109: The RePHILL Trial

by Salim Rezaie posted May 16, 2022 No Comments

Background: Currently, trauma resuscitation focuses on immediate hemorrhage control, resuscitation with blood products (i.e. PRBCs, plasma) and early administration of tranexamic acid. The evidence for the use of blood-based resuscitation in the pre-hospital system has been mixed (PAMPer and COMBAT ...

Hematology and OncologyTrauma

The INSPIRATION Trial: Intermediate Dose Anticoagulation in Critically Ill Patients with COVID-19

by Jessica DiPeri, MD posted April 4, 2022 No Comments

Background: COVID-19 infection increases the risk of thrombosis due to multiple factors.(Rico-Mesa, 2020). Over the last 2 years, researchers have published 12 RCTs investigating various anticoagulation strategies among patients diagnosed with COVID-19 in multiple clinical settings. To date, only a multiplatform ...

CardiovascularHematology and OncologyInfectious DiseaseThoracic and Respiratory

Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?

by Sarah Aly, DO posted February 28, 2022 No Comments

Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban and apixaban are associated with ICH at rates that range from 0.1 to 4% (Agnelli ...

Hematology and OncologyNeurologyTrauma

The MICHELLE Trial: Anticoagulation Post-Discharge in Patients Hospitalized Secondary to COVID-19

by Jessica DiPeri, MD posted February 14, 2022 No Comments

Background: Patients diagnosed with COVID-19 have an increased risk of thromboembolic events, including pulmonary embolism and deep vein thrombosis (DVT). In addition, COVID-19 patients with increased coagulation parameters such as D-dimer, fibrin degradation products, prothrombin time, and activated partial thromboplastin ...

CardiovascularHematology and OncologyInfectious DiseaseThoracic and Respiratory